Debra Bacon
Known title: EVP, MedicaidCIK: 0002010075
Associated companies
Transaction History
| MOH | ▼ Sell | Tax Withholding | 183 | $43K | 7/1/2026 | View on chart |
| MOH | ▲ Buy | Grant | 23 | $3K | 6/30/2026 | View on chart |
| MOH | ▼ Sell | Tax Withholding | 716 | $110K | 3/1/2026 | View on chart |
| MOH | ▲ Buy | Grant | 9,606 | $1.4M | 3/1/2026 | View on chart |
| MOH | ▲ Buy | Grant | 22 | $3K | 12/31/2025 | View on chart |
| MOH | ▼ Sell | Tax Withholding | 183 | $56K | 7/1/2025 | View on chart |
| MOH | ▲ Buy | Grant | 41 | $10K | 6/30/2025 | View on chart |
| MOH | ▲ Buy | Grant | 6,605 | $2.0M | 3/1/2025 | View on chart |
| MOH | ▼ Sell | Tax Withholding | 2,270 | $684K | 3/1/2025 | View on chart |
| MOH | ▼ Sell | Tax Withholding | 431 | $130K | 3/1/2025 | View on chart |
| MOH | ▲ Buy | Grant | 3,054 | $880K | 3/1/2025 | View on chart |
| MOH | ▼ Sell | Tax Withholding | 450 | $131K | 1/1/2025 | View on chart |
| MOH | ▲ Buy | Grant | 13 | $3K | 12/31/2024 | View on chart |
| MOH | ▼ Sell | Tax Withholding | 184 | $54K | 7/1/2024 | View on chart |
| MOH | ▲ Buy | Grant | 13 | $3K | 6/28/2024 | View on chart |
| MOH | ▼ Sell | Tax Withholding | 170 | $66K | 3/1/2024 | View on chart |
| MOH | ▲ Buy | Grant | 2,273 | $880K | 3/1/2024 | View on chart |
| MOH | ▼ Sell | Open Market | 500 | $198K | 2/14/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Molina Healthcare Draws Value Investor Interest Amid Recent Pressure
Diamond Hill Capital has highlighted long-term value in Molina Healthcare following recent stock price pressure. This view is echoed by other market analyses questioning if the stock is a value play. The company is currently trading near its 52-week low, with an average analyst target of $209.12.
Molina Healthcare Draws Value Investor Interest Amid Recent Pressure. Diamond Hill Capital has highlighted long-term value in Molina Healthcare following recent stock price pressure. This view is echoed by other market analyses questioning if the stock is a value play. The company is currently trading near its 52-week low, with an average analyst target of $209.12.